AMAG rises as Feraheme prospects broaden
This article was originally published in Scrip
AMAG Pharmaceuticals' attempts to broaden the label of its iron deficiency product Feraheme have made an encouraging start, prompting a short-lived 10% leap in its share price in after-hours trading.
You may also be interested in...
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.